logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Metastatic Castrationresistant Prostate Cancer

    FiltersReset Filters
    10 results

    • abiraterone

      (Abiraterone acetate)
      CivicaScript, LLC
      Usage: Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC).

    • abiraterone acetate

      (abiraterone acetate)
      Novugen Pharma (USA) LLC
      Usage: Abiraterone acetate tablets are indicated, in combination with prednisone, for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC).

    • abiraterone acetate

      (Abiraterone)
      AvKARE
      Usage: Abiraterone acetate tablets, in combination with prednisone, are indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC).

    • akeega

      (NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE)
      Janssen Biotech, Inc.
      Usage: AKEEGA, in combination with prednisone, is indicated for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Treatment selection should be based on an FDA-approved test for AKEEGA.

    • jevtana

      (cabazitaxel)
      Sanofi-Aventis U.S. LLC
      Usage: JEVTANA® is indicated for use with prednisone in treating patients with metastatic castration-resistant prostate cancer who have previously undergone treatment with a docetaxel-containing regimen.

    • rubraca

      (rucaparib)
      Clovis Oncology, Inc.
      Usage: Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.

    • rubraca

      (rucaparib)
      pharmaand GmbH
      Usage: Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.

    • talzenna

      (talazoparib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: TALZENNA is indicated for treating adult patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. It is also used in combination with enzalutamide for patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

    • yonsa

      (abiraterone acetate)
      Sun Pharmaceutical Industries, Inc.
      Usage: YONSA is indicated for use in combination with methylprednisolone to treat patients with metastatic castration-resistant prostate cancer.

    • zytiga

      (abiraterone acetate)
      Janssen Biotech, Inc.
      Usage: ZYTIGA is indicated for the treatment of metastatic castration-resistant prostate cancer (CRPC) and metastatic high-risk castration-sensitive prostate cancer (CSPC) when used in combination with prednisone.